Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cel-Sci Corp (AMEX:CVM) (was HIV) -- Ignore unavailable to you. Want to Upgrade?

To: Paul K who wrote (2735)	11/8/1999 11:40:00 AM
From: Toni Wheeler	Read Replies (1) \| Respond to of 2836

<<<CEL-SCI CORPORATION Announces Full Enrollment of Cancer Study VIENNA, Va., Nov. 8 /PRNewswire/ -- CEL-SCI CORPORATION (Amex: HIV; Berlin Stock Exchange: LSR) announces that its clinical investigators have completed enrollment of a 28 patient head and neck cancer study in Canada. The study involved the administration of the Company's proprietary immune boosting drug, Multikine(TM), as first line therapy for head and neck cancer patients scheduled for surgery or radiation. Results will be available as soon as the final report is completed by the Clinical Research Organization conducting the study. The study originally started with the goal of enrolling 14 patients at 2 doses but was subsequently increased to 21 patients and later to 28 patients. Multikine was injected at 4 doses 3 times per week around the tumor. Multikine is administered for only 2 weeks prior to the conventional therapy because it is unethical to delay the proven therapies, no matter how toxic and destructive they might be. Using the same protocol, but giving 5 injections per week for 2 weeks at only one of the four doses tested in Canada, the following results were seen in another trial in Israel: * All 10 patients had tumor reductions prior to surgery within a short time period. * 3 patients out of 10 had tumor reductions exceeding 50% and 1 patient, who had a tumor of 7 cm (nearly 3 inches) in diameter, had a complete clinical response with no measurable tumor remaining. * 2 patients refused surgery because they were satisfied with their condition after the treatment with Multikine. CEL-SCI has over 40 additional patients in other ongoing head and neck cancer studies involving minor variations of the same protocol. These studies should all finish enrolling in the next 3 to 6 months. CEL-SCI Corporation is a biopharmaceutical company whose mission is to use the immune system to combat disease. "CEL-SCI press releases are available through Company News On-Call by fax, (800) 758-5804, Ext. 445563, or at cel-sci.com on the Internet." When used in this report, the words "intends," "believes," "anticipated" and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, an inability to duplicate the clinic results demonstrated in preclinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products and the risk factors set forth from time to time in CEL-SCI Corporation's SEC filings, including but not limited to its report on Form 10-K for the year ended September 30, 1998. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. SOURCE CEL-SCI Corporation CO: CEL-SCI Corporation ST: Virginia IN: MTC BIO SU: 11/08/1999 09:01 EST prnewswire.com>>>